Variable | Patients with CIN-1-month N (%) (CIN-1 month positive) | Patients without CIN-1-month N (%) (CIN-1 month - ve) | P-value | |
---|---|---|---|---|
1 | Number | 69 (46.3 %) | 80 (53.7 %) | |
2 | Females | 29 (42.0 %) | 42 (52.5 %) | 0.20 |
3 | Older Adults (Age > 65 years) | 39 (56.5 %) | 39 (48.8 %) | 0.34 |
4 | EAP (versus validation cohort) | 33 (47.8 %) | 37 (46.3 %) | 0.85 |
5 | Primary site Colon (vs. Rectal) | 38 (55.1 %) | 50 (62.5 %) | 0.36 |
6 | RAS-wild type | 32 (46.4 %) | 41 (51.3 %) | 0.56 |
7 | High Baseline CEA (> 55 ng/ml) | 24 (34.7 %) | 43 (53.8 %) | 0.02* |
8 | Higher Baseline Neutrophil Count (> 4300/mm3) | 19 (27.5 %) | 55 (68.8 %) | <0.0001** |
9 | Overall disease control rate (DCR) | 32 (49.2 %) | 28 (37.8 %) | 0.18 |
-Partial Response (PR) | -4 (6.1 %) | -1 (1.3 %) | ||
-Stable Disease (SD) | -28 (43.1 %) | -27 (36.5 %) | ||
-Progressive Disease (PD) | -33 (50.8 %) | -46 (62.2 %) | ||
10 | Progression Free Survival (PFS) in months (95 % CI2) | 3.0 (2.3–3.6) | 2.4 (1.9–2.9) | 0.0096* |
11 | Overall Survival (OS) in months (95 % CI2) | 14.0 (11.2-NR1) | 5.6 (4.7–8.1) | <0.0001** |